vs

Side-by-side financial comparison of NorthWestern Energy Group, Inc. (NWE) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

NorthWestern Energy Group, Inc. is the larger business by last-quarter revenue ($497.6M vs $207.3M, roughly 2.4× Ultragenyx Pharmaceutical Inc.). NorthWestern Energy Group, Inc. runs the higher net margin — 12.8% vs -62.0%, a 74.8% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 6.6%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 24.7%).

NorthWestern Energy Group, Inc. is a utility company that serves South Dakota, Nebraska, and Montana that is based in Sioux Falls. As of 2019, the company serves approximately 718,000 customers. The company's corporate headquarters are located in Sioux Falls while the headquarters for the South Dakota operations are in Huron, South Dakota.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

NWE vs RARE — Head-to-Head

Bigger by revenue
NWE
NWE
2.4× larger
NWE
$497.6M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+19.2% gap
RARE
25.9%
6.6%
NWE
Higher net margin
NWE
NWE
74.8% more per $
NWE
12.8%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
24.7%
NWE

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
NWE
NWE
RARE
RARE
Revenue
$497.6M
$207.3M
Net Profit
$63.5M
$-128.6M
Gross Margin
Operating Margin
22.9%
-54.7%
Net Margin
12.8%
-62.0%
Revenue YoY
6.6%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NWE
NWE
RARE
RARE
Q1 26
$497.6M
Q4 25
$414.3M
$207.3M
Q3 25
$387.0M
$159.9M
Q2 25
$342.7M
$166.5M
Q1 25
$466.6M
$139.3M
Q4 24
$373.5M
$164.6M
Q3 24
$345.2M
$139.5M
Q2 24
$319.9M
$147.0M
Net Profit
NWE
NWE
RARE
RARE
Q1 26
$63.5M
Q4 25
$44.7M
$-128.6M
Q3 25
$38.2M
$-180.4M
Q2 25
$21.2M
$-115.0M
Q1 25
$76.9M
$-151.1M
Q4 24
$80.6M
$-133.2M
Q3 24
$46.8M
$-133.5M
Q2 24
$31.7M
$-131.6M
Operating Margin
NWE
NWE
RARE
RARE
Q1 26
22.9%
Q4 25
14.5%
-54.7%
Q3 25
20.7%
-106.9%
Q2 25
17.7%
-64.8%
Q1 25
26.7%
-102.6%
Q4 24
24.6%
-74.3%
Q3 24
19.7%
-94.6%
Q2 24
19.3%
-79.1%
Net Margin
NWE
NWE
RARE
RARE
Q1 26
12.8%
Q4 25
10.8%
-62.0%
Q3 25
9.9%
-112.8%
Q2 25
6.2%
-69.0%
Q1 25
16.5%
-108.5%
Q4 24
21.6%
-80.9%
Q3 24
13.6%
-95.7%
Q2 24
9.9%
-89.5%
EPS (diluted)
NWE
NWE
RARE
RARE
Q1 26
Q4 25
$0.72
$-1.28
Q3 25
$0.62
$-1.81
Q2 25
$0.35
$-1.17
Q1 25
$1.25
$-1.57
Q4 24
$1.31
$-1.34
Q3 24
$0.76
$-1.40
Q2 24
$0.52
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NWE
NWE
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-80.0M
Total Assets
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NWE
NWE
RARE
RARE
Q1 26
Q4 25
$8.8M
$421.0M
Q3 25
$6.2M
$202.5M
Q2 25
$2.9M
$176.3M
Q1 25
$56.0M
$127.1M
Q4 24
$4.3M
$174.0M
Q3 24
$2.5M
$150.6M
Q2 24
$6.4M
$480.7M
Total Debt
NWE
NWE
RARE
RARE
Q1 26
Q4 25
$3.3B
Q3 25
Q2 25
Q1 25
Q4 24
$3.0B
Q3 24
Q2 24
Stockholders' Equity
NWE
NWE
RARE
RARE
Q1 26
Q4 25
$2.9B
$-80.0M
Q3 25
$2.9B
$9.2M
Q2 25
$2.9B
$151.3M
Q1 25
$2.9B
$144.2M
Q4 24
$2.9B
$255.0M
Q3 24
$2.8B
$346.8M
Q2 24
$2.8B
$432.4M
Total Assets
NWE
NWE
RARE
RARE
Q1 26
Q4 25
$8.5B
$1.5B
Q3 25
$8.3B
$1.2B
Q2 25
$8.1B
$1.3B
Q1 25
$8.1B
$1.3B
Q4 24
$8.0B
$1.5B
Q3 24
$7.9B
$1.5B
Q2 24
$7.7B
$1.6B
Debt / Equity
NWE
NWE
RARE
RARE
Q1 26
Q4 25
1.14×
Q3 25
Q2 25
Q1 25
Q4 24
1.05×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NWE
NWE
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NWE
NWE
RARE
RARE
Q1 26
Q4 25
$56.2M
$-99.8M
Q3 25
$126.7M
$-91.4M
Q2 25
$58.2M
$-108.3M
Q1 25
$153.4M
$-166.5M
Q4 24
$62.8M
$-79.3M
Q3 24
$120.0M
$-67.0M
Q2 24
$62.3M
$-77.0M
Free Cash Flow
NWE
NWE
RARE
RARE
Q1 26
Q4 25
$-93.7M
$-100.8M
Q3 25
$-26.9M
$-92.7M
Q2 25
$-70.6M
$-110.7M
Q1 25
$61.3M
$-167.8M
Q4 24
$-85.9M
$-79.5M
Q3 24
$-33.2M
$-68.6M
Q2 24
$-76.3M
$-79.0M
FCF Margin
NWE
NWE
RARE
RARE
Q1 26
Q4 25
-22.6%
-48.6%
Q3 25
-6.9%
-58.0%
Q2 25
-20.6%
-66.5%
Q1 25
13.1%
-120.5%
Q4 24
-23.0%
-48.3%
Q3 24
-9.6%
-49.2%
Q2 24
-23.9%
-53.7%
Capex Intensity
NWE
NWE
RARE
RARE
Q1 26
Q4 25
36.2%
0.5%
Q3 25
39.7%
0.8%
Q2 25
37.6%
1.5%
Q1 25
19.7%
1.0%
Q4 24
39.8%
0.1%
Q3 24
44.4%
1.2%
Q2 24
43.3%
1.4%
Cash Conversion
NWE
NWE
RARE
RARE
Q1 26
Q4 25
1.26×
Q3 25
3.31×
Q2 25
2.74×
Q1 25
1.99×
Q4 24
0.78×
Q3 24
2.56×
Q2 24
1.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NWE
NWE

Electric$362.1M73%
Gas$135.5M27%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons